miR-155, miR-191, and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of Avastin on these biomarkers
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: Oral squamous cell carcinoma (OSCC) is one of the most common types of head and neck cancer. MicroRNAs, as new biomarkers, are recommended for diagnosis and treatment of different types of cancers. Bevacizumab, sold under the trade name Avastin, is a humanized whole monoclonal antibody that targets and blocks VEGF-A (vascular endothelial growth factor A; angiogenesis) and oncogenic signaling pathways. Materials and Methods: This study comprised 50 cases suffering from OSCC and 50 healthy participants. Peripheral blood samples were collected in glass test tubes, and RNA extraction was started immediately. Expression levels of miR-155, miR-191, and miR-494 biomarkers in the peripheral blood of OSCC-affected individuals and healthy volunteers in vivo were evaluated using real-time PCR. The influence of Avastin on the expression levels of the aforementioned biomarkers in vitro and in the HN5 cell line was also investigated. Results: Expression levels of miR-155, miR-191, and miR-494 in the peripheral blood of individuals affected by OSCC were higher than in those who were healthy. Moreover, Avastin at a concentration of 400 μM caused a decrease in the expression levels of the three biomarkers and a 1.5-fold, 3.5-fold, and 4-fold increase in apoptosis in the test samples compared to the controls in the HN5 cell line after 24, 48, and 72 hours, respectively. Conclusion: The findings of this study demonstrate that overexpression of miR-155, miR-191, and miR-494 is associated with OSCC, and Avastin is able to regulate and downregulate the expression of those biomarkers and increase apoptosis in cancerous cells in the HN5 cell line.
Abstract
Objectives: Oral squamous cell carcinoma (OSCC) is one of the most common types of head and neck cancer. MicroRNAs, as new biomarkers, are recommended for diagnosis and treatment of different types of cancers. Bevacizumab, sold under the trade name Avastin, is a humanized whole monoclonal antibody that targets and blocks VEGF-A (vascular endothelial growth factor A; angiogenesis) and oncogenic signaling pathways. Materials and Methods: This study comprised 50 cases suffering from OSCC and 50 healthy participants. Peripheral blood samples were collected in glass test tubes, and RNA extraction was started immediately. Expression levels of miR-155, miR-191, and miR-494 biomarkers in the peripheral blood of OSCC-affected individuals and healthy volunteers in vivo were evaluated using real-time PCR. The influence of Avastin on the expression levels of the aforementioned biomarkers in vitro and in the HN5 cell line was also investigated. Results: Expression levels of miR-155, miR-191, and miR-494 in the peripheral blood of individuals affected by OSCC were higher than in those who were healthy. Moreover, Avastin at a concentration of 400 μM caused a decrease in the expression levels of the three biomarkers and a 1.5-fold, 3.5-fold, and 4-fold increase in apoptosis in the test samples compared to the controls in the HN5 cell line after 24, 48, and 72 hours, respectively. Conclusion: The findings of this study demonstrate that overexpression of miR-155, miR-191, and miR-494 is associated with OSCC, and Avastin is able to regulate and downregulate the expression of those biomarkers and increase apoptosis in cancerous cells in the HN5 cell line.
참고문헌 (45)
- Kumar M, "Oral cancer : etiology and risk factors : a review", J Cancer Res Ther, 12, pp.458~463 (2016)[DOI]
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)[DOI]
- Peng Y, "The role of MicroRNAs in human cancer", Signal Transduct Target Ther, 1, pp.15004~ (2016)[DOI]
- Nagpal N, "miR-191 : an emerging player in disease biology", Front Genet, 5, pp.99~ (2014)[DOI]
- Stahlhut Espinosa CE, "The role of microRNAs in cancer", Yale J Biol Med, 79, pp.131~140 (2006)
- Sun Y, "Serum microRNA-155 as a potential biomarker to track disease in breast cancer", PLoS One, 7, pp.e47003~ (2012)[DOI]
- Zhang X, "Amplification of hsa-miR-191", 425 locus promotes breast cancer proliferation and metastasis by targeting DICER1, 2018, pp.39, 1506~1516
- Chen J, "MicroRNA-494 promotes tumor growth by targeting PTEN in non-small cell lung cancer", Int J Clin Exp Pathol, 10, pp.4441~4450 (2017)
- Qu Y, "MicroRNA-155promotes gastric cancer growth and invasion by negatively regulating transforming growth factor-β receptor 2", Cancer Sci, 109, pp.618~628 (2018)[DOI]
- Peng WZ, "Role of miR-191", 425 cluster in tumorigenesis and diagnosis of gastric cancer, 2014, pp.15, 4031~4048
- He W, "miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc", J Gastroenterol Hepatol, 29, pp.1427~1434 (2014)[DOI]
- Shi LJ, "MicroRNA-155 in oral squamous cell carcinoma : overexpression, localization, and prognostic potential", Head Neck, 37, pp.970~976 (2015)[DOI]
- Gissi DB, "A noninvasive test for MicroRNA expression in oral squamous cell carcinoma", Int J Mol Sci, 19, pp.1789~ (2018)[DOI]
- Libório-Kimura TN, "miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer", Oral Oncol, 51, pp.151~157 (2015)[DOI]
- Zahra A, "Metaanalysis of miRNAs and their involvement as biomarkers in oral cancers", Biomed Res Int, 2018, pp.8439820~ (2018)[DOI]
- Troiano G, "Predictive prognostic value of tissue-based microRNA expression in oral squamous cell carcinoma: a systematic review and meta-analysis", J Dent Res, 97, pp.759~766 (2018)[DOI]
- Patel RS, "High resolution of microRNA signatures in human whole saliva", Arch Oral Biol, 56, pp.1506~1513 (2011)[DOI]
- Shi X, "MicroRNA-191 targets Ndeacetylase", N-sulfotransferase 1 and promotes cell growth in human gastric carcinoma cell line MGC803, 2011, pp.43, 849~856
- Bedewy AML, "Prognostic value of miRNA-155 expression in B-cell non-hodgkin lymphoma", Turk J Haematol, 34, pp.207~212 (2017)[DOI]
- Iorio MV, "microRNA involvement in human cancer", Carcinogenesis, 33, pp.1126~1133 (2012)[DOI]
- Pollutri D, "The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma", Cell Death Dis, 9, pp.4~ (2018)[DOI]
- Shih T, "Bevacizumab : an angiogenesis inhibitor for the treatment of solid malignancies", Clin Ther, 28, pp.1779~1802 (2006)[DOI]
- Pang W, "Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts", Cancer Sci, 106, pp.1362~1369 (2015)[DOI]
- de Gramont A, "Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer", Oncology, 69(Suppl 3), pp.46~56 (2005)[DOI]
- Yoshida H, "Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model : a preliminary study", Oncol Lett, 15, pp.8627~8634 (2018)[DOI]
- Zhao XM, "Identifying cancer-related microRNAs based on gene expression data", Bioinformatics, 31, pp.1226~1234 (2015)[DOI]
- Shah MY, "microRNA therapeutics in cancer-an emerging concept", EBioMedicine, 12, pp.34~42 (2016)[DOI]
- Hammond SM, "MicroRNAs as oncogenes", Curr Opin Genet Dev, 16, pp.4~9 (2006)[DOI]
- Hutvágner G, "A microRNA in a multiple-turnover RNAi enzyme complex", Science, 297, pp.2056~2060 (2002)[DOI]
- Kroh EM, "Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR(qRT-PCR)", Methods, 50, pp.298~301 (2010)[DOI]
- Xue X, "MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN", Oncotarget, 7, pp.84508~84519 (2016)[DOI]
- Lu S, "MiR-155 affects osteosarcoma cell proliferation and invasion through regulating NF-κB signaling pathway", Eur Rev Med Pharmacol Sci, 22, pp.7633~7639 (2018)[DOI]
- Zare A, "Decreased miR-155-5p, miR-15a, and miR-186expression in gastric cancer is associated with advanced tumor grade and metastasis", Iran Biomed J, 23, pp.338~343 (2019)[DOI]
- Elyakim E, "hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy", Cancer Res, 70, pp.8077~8087 (2010)[DOI]
- Liu H, "MicroRNA-191 promotes pancreatic cancer progression by targeting USP10", Tumour Biol, 35, pp.12157~12163 (2014)[DOI]
- Zhang XF, "miR-191promotes tumorigenesis of human colorectal cancer through targeting C", EBPβ, 2015, pp.6, 4144~4158
- Colamaio M, "miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting", J Clin Endocrinol Metab, 96, pp.E1915~E1924 (2011)[DOI]
- Chen P, "MicroRNA-191-5p exerts a tumor suppressive role in renal cell carcinoma", Exp Ther Med, 15, pp.1686~1693 (2018)[DOI]
- Macedo T, "Overexpression of mir-183 and mir-494 promotes proliferation and migration in human breast cancer cell lines", Oncol Lett, 14, pp.1054~1060 (2017)[DOI]
- Liu K, "miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN", Oncol Rep, 34, pp.1003~1010 (2015)[DOI]
- Zhang Y, "MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer", Mol Cancer, 17, pp.1~ (2018)[DOI]
- Yang YK, "MicroRNA-494promotes cervical cancer proliferation through the regulation of PTEN", Oncol Rep, 33, pp.2393~2401 (2015)[DOI]
- Yuan J, "MiR-494 inhibits epithelial ovarian cancer growth by targeting c-Myc", Med Sci Monit, 22, pp.617~624 (2016)[DOI]
- Zhao Z, "Autophagy inhibition promotes bevacizumab-induced apoptosis and proliferation inhibition in colorectal cancer cells", J Cancer, 9, pp.3407~3416 (2018)[DOI]
- Kang YK, "Capecitabine", cisplatin versus 5-fluorouracil, Ann Oncol, pp.2009, 20[DOI]